166 related articles for article (PubMed ID: 1929292)
21. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine.
Rosowsky A; Queener SF; Cody V
Drug Des Discov; 1999 Jul; 16(1):25-40. PubMed ID: 10466054
[TBL] [Abstract][Full Text] [Related]
22. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
Kovacs JA; Allegra CJ; Kennedy S; Swan JC; Drake J; Parrillo JE; Chabner B; Masur H
Am J Trop Med Hyg; 1988 Nov; 39(5):491-6. PubMed ID: 2973755
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Rosowsky A; Cody V; Galitsky N; Fu H; Papoulis AT; Queener SF
J Med Chem; 1999 Nov; 42(23):4853-60. PubMed ID: 10579848
[TBL] [Abstract][Full Text] [Related]
25. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR
J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140
[TBL] [Abstract][Full Text] [Related]
26. Purification and properties of recombinant Pneumocystis carinii dihydrofolate reductase.
Sirawaraporn W; Edman JC; Santi DV
Protein Expr Purif; 1991; 2(5-6):313-6. PubMed ID: 1821803
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
[TBL] [Abstract][Full Text] [Related]
28. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Graffner-Nordberg M; Kolmodin K; Aqvist J; Queener SF; Hallberg A
J Med Chem; 2001 Jul; 44(15):2391-402. PubMed ID: 11448221
[TBL] [Abstract][Full Text] [Related]
30. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.
Walzer PD; Kim CK; Foy JM; Linke MJ; Cushion MT
Antimicrob Agents Chemother; 1988 Jan; 32(1):96-103. PubMed ID: 3258144
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
33. Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
Shah K; Queener S; Cody V; Pace J; Gangjee A
Bioorg Med Chem Lett; 2019 Aug; 29(15):1874-1880. PubMed ID: 31176699
[TBL] [Abstract][Full Text] [Related]
34. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.
Walzer PD; Foy J; Steele P; Kim CK; White M; Klein RS; Otter BA; Allegra C
Antimicrob Agents Chemother; 1992 Sep; 36(9):1935-42. PubMed ID: 1416884
[TBL] [Abstract][Full Text] [Related]
35. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
[TBL] [Abstract][Full Text] [Related]
36. Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
Stevens MF; Phillip KS; Rathbone DL; O'Shea DM; Queener SF; Schwalbe CH; Lambert PA
J Med Chem; 1997 Jun; 40(12):1886-93. PubMed ID: 9191966
[TBL] [Abstract][Full Text] [Related]
37. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
Allegra CJ; Chabner BA; Tuazon CU; Ogata-Arakaki D; Baird B; Drake JC; Simmons JT; Lack EE; Shelhamer JH; Balis F
N Engl J Med; 1987 Oct; 317(16):978-85. PubMed ID: 2958710
[TBL] [Abstract][Full Text] [Related]
38. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
[TBL] [Abstract][Full Text] [Related]
39. Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase.
Gschwend DA; Sirawaraporn W; Santi DV; Kuntz ID
Proteins; 1997 Sep; 29(1):59-67. PubMed ID: 9294866
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
Cirioni O; Giacometti A; Scalise G
J Antimicrob Chemother; 1997 Jan; 39(1):45-51. PubMed ID: 9044027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
